Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEAT COVID-19 adaptive outpatient treatment trial
ACTRN12620000566932Phase 3Terminated
- Sponsor
- University of Sydney
- Start
- Mar 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ciclesonide in coronavirus disease 2019 (COVID-19), sponsored by University of Sydney. Primary endpoint: Time to first recovery within 28 days. Started Mar 2022; status: terminated.
02
Drugs
ciclesonide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ACTRN12620000566932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000566932.